No price history available.
Key financial summary
Financials in TWD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | TWDm | 222 | 217 | 270 | 237 | 119 | 0 | N/A | N/A |
| Operating profit | TWDm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | TWDm | -129 | -181 | -153 | -289 | -183 | -111 | N/A | N/A |
| EPS reported | TWD | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | TWD | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | TWD | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | TWD | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | TWDm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | TWDm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | TWDm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | TWD | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | TWD | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in TWD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | |||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | |||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | |||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Holy Stone Healthcare Co., Ltd., together with its subsidiaries, develops and sells hyaluronic acid-related therapeutic products in Taiwan. The company offers RenehaVis and SportVis, which are injectable medical devices for osteoarthritis and soft tissue injuries; TRUD, a medical device that contains a mixture of hyaluronic acid used for the treatment and prevention of ulcerative colitis in inflammatory bowel disease (IBD); and GAF, a gel for anal fissure healing. It also develops IBD98-M, an oral capsule that is in a Phase IIa trial for ulcerative colitis; CA102N, a receptor-targeted chemotherapy that is in a Phase II trial for metastatic colorectal cancer, as well as in a pre-clinical stage for pancreatic ductal adenocarcinoma and a discovery stage for triple-negative breast cancer; ND108E, a CNS-targeted HA conjugate that is in a pre-clinical trial for Alzheimer’s disease; AMD112, a non-invasive HA-conjugated small molecule therapy that is in a pre-clinical trial for wet age-related macular degeneration and other neovascular retinal diseases; and HylCaryo, a hyaluronic acid (HA)-derived nanoparticle platform in a discovery stage. In addition, the company engages in general investment; development and sale of medical devices; biotechnology services; and patent application for pharmaceutical products. Holy Stone Healthcare Co., Ltd. was founded in 2001 and is headquartered in Taipei, Taiwan.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Holy Stone Healthcare Co., Ltd. (4194.TWO)
No price history available.
Not enough data to calculate KvantraRank
Based on consensus from external analysts. Not Kvantra's opinion.
Holy Stone Healthcare Co., Ltd., together with its subsidiaries, develops and sells hyaluronic acid-related therapeutic products in Taiwan. The company offers RenehaVis and SportVis, which are injectable medical devices for osteoarthritis and soft tissue injuries; TRUD, a medical device that contains a mixture of hyaluronic acid used for the treatment and prevention of ulcerative colitis in inflammatory bowel disease (IBD); and GAF, a gel for anal fissure healing. It also develops IBD98-M, an oral capsule that is in a Phase IIa trial for ulcerative colitis; CA102N, a receptor-targeted chemotherapy that is in a Phase II trial for metastatic colorectal cancer, as well as in a pre-clinical stage for pancreatic ductal adenocarcinoma and a discovery stage for triple-negative breast cancer; ND108E, a CNS-targeted HA conjugate that is in a pre-clinical trial for Alzheimer’s disease; AMD112, a non-invasive HA-conjugated small molecule therapy that is in a pre-clinical trial for wet age-related macular degeneration and other neovascular retinal diseases; and HylCaryo, a hyaluronic acid (HA)-derived nanoparticle platform in a discovery stage. In addition, the company engages in general investment; development and sale of medical devices; biotechnology services; and patent application for pharmaceutical products. Holy Stone Healthcare Co., Ltd. was founded in 2001 and is headquartered in Taipei, Taiwan.